Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58

被引：0
|
作者：
Zelniker, T. A. [1 ,2 ]
Raz, I. [3 ]
Mosenzon, O. [3 ]
Dwyer, J. P. [4 ]
Heerspink, H. J. L. [5 ]
Cahn, A. [3 ]
Im, K. [1 ,2 ]
Bhatt, D. L. [1 ,2 ]
Leiter, L. A. [6 ]
McGuire, D. K. [7 ]
Wilding, J. P. H. [8 ]
Gause-Nilsson, I. A. M. [9 ]
Langkilde, A. M. [9 ]
Sabatine, M. S. [1 ,2 ]
Wiviott, S. D. [1 ,2 ]
机构：
[1] Brigham & Womens Hosp, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Hadassah Univ, Med Ctr, Jerusalem, Israel
[4] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
[5] Univ Med Ctr Groningen, Groningen, Netherlands
[6] Univ Toronto, Toronto, ON, Canada
[7] Univ Texas Southwestern Med Sch, Dallas, TX USA
[8] Univ Liverpool, Liverpool, Merseyside, England
[9] AstraZeneca, Gothenburg, Sweden
来源：
EUROPEAN HEART JOURNAL | 2019年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
192
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [21] Dapagliflozin reduces the risk of hospitalization in patients with type 2 diabetesNew results from the DECLARE-TIMI 58 study
    Schamarek, Imke
    DIABETOLOGIE, 2023, 19 (05): : 702 - 704
  • [22] Letter by Chen et al Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial"
    Chen, Zhi-Qing
    Chen, Feng
    Li, Lang
    CIRCULATION, 2020, 142 (10) : E127 - E128
  • [23] FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58
    Berg, David
    Wiviott, Stephen D.
    Raz, Itamar
    Jarolim, Petr
    Goodrich, Erica L.
    Mosenzon, Ofri
    Cahn, Avivit
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid
    Hammarstedt, Ann
    Oscarsson, Jan
    Sabatine, Marc Steven
    Morrow, David A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1526 - 1526
  • [24] Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
    Mosenzon, Ofri
    Wiviott, Stephen D.
    Cahn, Avivit
    Rozenberg, Aliza
    Yanuv, Ilan
    Goodrich, Erica L.
    Murphy, Sabina A.
    Heerspink, Hiddo J. L.
    Zelniker, Thomas A.
    Dwyer, Jamie P.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Kato, Eri T.
    Gause-Nilson, Ingrid A. M.
    Fredriksson, Martin
    Johansson, Peter A.
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Raz, Itamar
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (08): : 606 - 617
  • [25] Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
    Mosenzon, Ofri
    Raz, Itamar
    Wiviott, Stephen D.
    Schechter, Meir
    Goodrich, Erica L.
    Yanuv, Ilan
    Rozenberg, Aliza
    Murphy, Sabina A.
    Zelniker, Thomas A.
    Langkilde, Anna Maria
    Gause-Nilsson, Ingrid A. M.
    Fredriksson, Martin
    Johansson, Peter A.
    Wilding, John P. H.
    McGuire, Darren K.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    Cahn, Avivit
    Dwyer, Jamie P.
    Heerspink, Hiddo J. L.
    Sabatine, Marc S.
    DIABETES CARE, 2022, 45 (10) : 2350 - 2359
  • [26] Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes A Prespecified Secondary Analysis of a Randomized Clinical Trial
    Zelniker, Thomas A.
    Raz, Itamar
    Mosenzon, Ofri
    Dwyer, Jamie P.
    Heerspink, Hiddo H. J. L.
    Cahn, Avivit
    Goodrich, Erica L.
    Im, Kyungah
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Wiviott, Stephen D.
    JAMA CARDIOLOGY, 2021, 6 (07) : 801 - 810
  • [27] Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial"
    Zelniker, Thomas A.
    Raz, Itamar
    Sabatine, Marc S.
    Wiviott, Stephen D.
    CIRCULATION, 2020, 142 (10) : E129 - E130
  • [28] SOLUBLE SUPPRESSION OF TUMORIGENICITY 2 (SST2) AND CARDIOVASCULAR OUTCOMES IN PERSONS WITH TYPE 2 DIABETES MELLITUS RANDOMIZED TO DAPAGLIFLOZIN OR PLACEBO: ANALYSES FROM THE DECLARE-TIMI 58 TRIAL
    Haller, Paul
    Wiviott, Stephen
    Jarolim, Petr
    Goodrich, Erica L.
    Bhatt, Deepak L.
    Gause-Nilsson, Ingrid
    Leiter, Lawrence A.
    McGuire, Darren K.
    Raz, Itamar
    Wilding, John
    Sabatine, Marc Steven
    Morrow, David A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 378 - 378
  • [29] Effect of Dapagliflozin in Reducing Recurrent Myocardial Infarction of Different Infarct Types and Sizes: Insights From Declare-Timi 58
    Furtado, Remo H.
    Bonaca, Marc P.
    Zelniker, Thomas A.
    Raz, Itamar
    Goodrich, Erica
    Mosenzon, Ofri
    Murphy, Sabina
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John
    Gause-Nilsson, Ingrid A.
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Wiviott, Stephen
    CIRCULATION, 2019, 140
  • [30] Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
    Schechter, Meir
    Wiviott, Stephen
    Raz, Itamar
    Goodrich, Erica L.
    Rozenberg, Aliza
    Yanuv, Ilan
    Murphy, Sabina A.
    Zelniker, Thomas A.
    Fredriksson, Martin
    Johansson, Peter A.
    Leiter, Lawrence A.
    Bhatt, Deepak L.
    McGuire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid A. M.
    Cahn, Avivit
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Mosenzon, Ofri
    LANCET DIABETES & ENDOCRINOLOGY, 2023, 11 (04): : 233 - 241
12345